KRAS and non-small cell lung carcinoma: One of these compounds (AMG-510 or Sotorasib) acts by holding K-RAS G12C in its GDP-bound inactive form and has recently been granted accelerated approval for the treatment of K-RAS G12C-mutated (7) locally advanced or metastatic NSCLC using a specific companion diagnostic (8).